VCYTHealthcare · Diagnostics & ResearchThe 13 Wall Street analysts covering Veracyte, Inc. hold a median 12-month price target of $59 — +35.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Veracyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (64): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VCYT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +35.6% from it.
Of the 20 most recent actions, 5 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Sept 2026 | Freedom Capital Markets | Maintains | Buy | $66 |
| 9 Sept 2026 | UBS | Maintains | Buy | $52 → $65 |
| 4 Aug 2026 | Morgan Stanley | Maintains | Underweight | — |
| 4 Aug 2026 | Morgan Stanley | Maintains | Underweight | $47 → $44 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | $66 → $54 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | $68 → $55 |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Hold | $60 → $50 |
| 31 July 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Needham | Maintains | Buy | $57 → $69 |
| 30 July 2026 | Needham | Maintains | Buy | $57 → $69 |
| 30 July 2026 | Needham | Maintains | Buy | — |
| 15 July 2026 | Piper Sandler | Initiates | Overweight | $66 |
| 15 July 2026 | Piper Sandler | Initiates | Overweight | — |
| 14 July 2026 | Canaccord Genuity | Maintains | Hold | $42 → $60 |
| 14 July 2026 | Canaccord Genuity | Maintains | Hold | — |
| 9 July 2026 | Morgan Stanley | Maintains | Underweight | $37 → $47 |
| 9 July 2026 | Morgan Stanley | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VCYT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Veracyte, Inc. returned +28.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 25% of US stocks
Cheaper than 20% of US stocks
Cheaper than 36% of US stocks
Cheaper than 10% of US stocks
Higher than 63% of US stocks
Higher than 53% of US stocks
Higher than 85% of US stocks
Higher than 73% of US stocks
Higher than 82% of US stocks
Higher than 61% of US stocks
Higher than 71% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Veracyte, Inc. has a market value of $3.5B and an enterprise value of $3.1B.
Revenue in the twelve months to 30 June 2026: $561.9M. The latest quarter grew 15.5% year on year.
Net income over the same four quarters: $114.5M, a 20.4% net margin.
Diluted earnings per share, trailing twelve months: $1.41.
Free cash flow in the twelve months to 30 June 2026: $166.0M.
Trailing P/E: 30.8×; forward P/E: 22.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Veracyte, Inc. employs 755 people — $744K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Veracyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Veracyte announced that it will release its third-quarter 2026 financial results after the market closes on November 4, 2026.
Why it matters — VCYT watchers can note the scheduled date for the company's quarterly results.
Veracyte announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 ASTRO Annual Meeting. The analysis demonstrates that the company's Decipher Prostate test predicts benefit from adding hormone therapy to radiation.
Why it matters — The presentation of phase III trial data supporting Decipher Prostate's predictive value strengthens the clinical evidence for one of Veracyte's key diagnostic products.
Veracyte announced that eight Decipher-focused studies—six oral presentations and two posters—will be presented at ASTRO 2026. The studies will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and their likelihood of benefiting from treatment intensification.
Why it matters — For VCYT watchers, the presentation of multiple Decipher studies at a major oncology conference could raise visibility and further validate the clinical utility of one of the company's key products.
Veracyte's share price jumped 10.8% in the last session on above-average trading volume. However, the latest trend in earnings estimate revisions for the stock does not suggest further strength down the road.
Why it matters — For VCYT watchers, the share price surge contrasts with an absence of supportive earnings estimate revisions, offering a signal about the stock's near-term outlook.
Veracyte, Inc. (VCYT) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published by Seeking Alpha. The item reports on the company's participation in this investor conference.
Why it matters — A VCYT watcher would care because the conference presentation gives investors insight into management's public statements and the company's positioning at a major healthcare industry event.
The 13 Wall Street analysts covering Veracyte, Inc. have a median 12-month price target of $59, with estimates ranging from $44 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Veracyte, Inc., 11 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Veracyte, Inc. 96 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Veracyte, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +35.6% from the last close, and Ticker Nerd's factor model ranks Veracyte, Inc. 96 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Veracyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCYT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $70 over the next 12 months.
Veracyte, Inc. returned +28.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026". Veracyte announced that it will release its third-quarter 2026 financial results after the market closes on November 4, 2026.
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases. Veracyte’s current portfolio includes laboratory-developed tests for thyroid, prostate, bladder, and breast cancer, as well as tests for lung disease and lung cancer-related decision support. The company also provides products and services such as Afirma, Decipher, Percepta, Envisia, Prosigna, Immunoscore, and nCounter analysis capabilities, supporting diagnosis, prognosis, and treatment selection across multiple care settings. Its work is centered on using genomic and clinical data to reduce diagnostic uncertainty and improve decision-making for physicians, pathologists, and patients. Headquartered in South San Francisco, California, Veracyte operates as a global diagnostics business with a focus on molecular testing, evidence generation, and clinical utility in oncology and related specialties.
CEO Mr. Marc A. Stapley · 755 employees · United States · https://www.veracyte.com
